Investigating the Impact of Cell Inclination on Phase Change Material Melting in Square Cells: A Numerical Study

In order to determine the ideal degree of inclination that should be employed for constructing effective thermal energy storage systems, it is important to examine the impact of inclination angle on the melting behavior of phase change materials (PCMs) such as paraffin wax within a square cell. In consequence, this would guarantee the greatest capacity for energy release and storage. Additionally, analyzing this influence aids engineers in creating systems that enhance heat flow from external sources to the PCM and vice versa. To find out how the cell’s inclination angle affects the melting of PCM of paraffin wax (RT42) inside a square cell, a numerical analysis is carried out using the ANSYS/FLUENT 16 software. Specifically, the temperature and velocity distributions, together with the evolution of the melting process, will be shown for various inclination angles, and a thorough comparison will be made to assess the influence of inclination angle on the PCM melting process and its completion. The findings demonstrated that when the cell’s inclination angle increased from 0° to 15° and from 0° to 30° and 45°, respectively, the amount of time required to finish the melting process increased by 15%, 42%, and 71%, respectively. Additionally, after 210 min of operation, the PCM’s maximum temperature is 351.5 K with a 0° angle of inclination (horizontal) against 332.5 K with an angle of inclination of 45°

Immunohistochemical Expression of CD68 in Triple Negative Invasive Ductal Carcinoma of the Breast and its Correlation with Clinicopathological Parameters

Introduction: Triple negative breast cancer (TNBC) is an aggressive form of breast cancer associated with a poor prognosis. No targeted treatment is available for this subtype. Tumor microenvironment (TME) has been increasingly considered a diagnostic and a prognostic biomarker and a therapeutic target for breast cancer. Tumor associated macrophages (TAM) are a pivotal member of TME and have been proposed as potential targets of therapy. Material and Methods: The immunohistochemical expression of CD68+ve TAM was studied in both tumor stroma (TS) and tumor nest (TN) in 50 cases of triple negative invasive ductal carcinoma as well as in 10 control cases of benign breast lesions. Results: The cases were divided into high or low density groups according to the median. The median in CD68+ve TAM in TS was (61.88), while in CD68+ve TAM in TN was (49.88). The expression of CD68+ve TAM in TS was low in 22 cases and high in 28 cases, while its expression in TN was low in 35 cases and high in 15 cases. There was no statistical association between high CD68+ve TAM in TN and different clinicopathological parameters, meanwhile a statistically significant association was found between high CD68 +ve TAM in TS and tumor grade, lymph/vascular invasion and lymph node metastasis. Conclusions: High expression of TAM in TS, but not in TN, is of clinical significance in patients with TNBC and highlights the importance of analyzing the localization rather than merely the presence of TAM as a marker for prognosis and a potential target for future treatment of triple negative breast cancer. </jats:sec

Epidemiological, clinical and pharmacological aspects of headache in a university undergraduate population in Palestine

Headache is one of the most common complaints in clinical practice. Few studies regarding headache in university students have been conducted in the Middle East. The objective of this study was to explore the prevalence, clinical characteristics, triggering factors and treatment options of headaches in university undergraduate students in Palestine/Middle East. Data were collected by interviewing a sample of 1900 students. The Headache Assessment Quiz was used to measure quality and severity of headache and to collect data on triggering factors and symptom management. A total of 1808 (95.2%) reported having at least one headache episode in the previous year. A positive family history of headache was found in 40% of students. The prevalence rate of frequent headache (tow or more episodes/month) was found in 1096 (60.9%) students; 613 women (55.9%). Of those having frequent headaches, 228 (20.8%) experienced moderate to severe episodes, 341 (31.2%) had pulsating, throbbing and pounding pain, and 274 (25%) had unilateral pain. The most common triggering factors among students with frequent headaches were: tension/stress (78.2%) and sleep deprivation (75.4%). Less than 5% of students sought medical assistance during headache episodes. Most students (79.1%) reported self-therapy with a single analgesic (53.4%), herbs (10.2%) or combination (15.5%), while 20.9% reported using no medication of any type to decrease pain. Paracetamol (48.5%) followed by ibuprofen (4.9%) were the most commonly used non-prescription analgesic drugs. Headache is a prevalent symptom in the college age population. Further research is needed to determine the prevalence of specific types of headaches. Healthcare providers are required to educate this population as well as to assist students in properly diagnosing and treating headache types. </jats:p

CLINICAL PROGNOSTIC FACTORS IN PATIENTS WITH ADVANCED STAGE OF PROSTATE CANCER

Objectives: To determine the prognostic factors that could predict patient outcome in patients with advanced stage prostate cancer. Patients and Methods: In this study we retrospectively evaluated the medical record data of 222 patients with advanced stage prostate cancer treated by hormonal therapy (either castration or total androgen blockade (TAB)). All pre- and post- treatment data records were evaluated with respect to patient age, prostate and tumor size, tumor grade, stage, PSA, alkaline and acid phosphatase and the number of bone lesions. The response to the hormonal treatment was evaluated either early (12 months after treatment) or late (over all follow-up visits until the last visit or death). Descriptive statistics, student T test, multivariate and Kaplan Meier's curve were used for data analysis. Results: Within 12 months of treatment 70% of the cases showed an improvement with a significant decrease of their pre-treatment values after hormonal therapy. Patient age, tumor stage, the number of bone lesions, serum alkaline and acid phosphatase levels in the pre-treatment data were significantly independent predictors of the overall survival outcome (p= 0.0015, 0.002, 0.001, 0.0002 and 0.028, respectively), while the pre-treatment PSA serum level, tumor grade and the type of hormonal treatment used (either castration or TAB) were no predictors of patient outcome (p= 0.18, 0.82 and 0.47, respectively). Importantly, the PSA serum level and the number of bone lesions in the first 12 months of patient follow-up were significant predictors of the overall disease survival status (p=0.001 and 0.028, respectively). The mean follow-up period of alive cases was 39.42 months ranging from 6 – 171 months. Of the 222 cases 110 (51.6%) had overall disease progression during a mean of 59.4 months, while mortality was reported in 118 cases (53.2%) in the course of a mean of 59.9 months.Conclusion: The pre-treatment patient age, tumor stage, serum alkaline and acid phosphatase, as well as the post-treatment PSA level and the number of bone lesions were significant independent predictors of the overall patient outcome inpatients with advanced stage prostate cancer. However, a survival analysis in relation to the treatment type did not reveal a statistically significant difference between the outcomes of castration and TAB. Facteurs Pronostiques Cliniques chez les Patients Atteints de Cancer Prostatique Avancé Objectifs: De déterminer les facteurs pronostiques prédictifs de l'évolution du cancer prostatique chez nos patients atteints de cancer avancé de la prostate. Patients et Méthodes: Dans cette étude nous avons rétrospectivement évalué les données médicales de 222 patients atteints de cancer avancé de la prostate traités par thérapie hormonale (castration ou blocage androgènique total (BAT)). Toutes les données pré et post ont été évaluées en ce qui concerne l'âge des patients, la taille de la prostate et de la tumeur, le score histologique de la tumeur, le stade clinique, le PSA, la phosphatase alkaline et acide et le nombre de lésions osseuses. La réponse au traitement hormonal a été évaluée aussi bien tôt (12 mois après traitement) ou tard (à la dernière visite ou mort). Des statistiques descriptives, les tests T de Student, multivariable et de Kaplan Meier ont été employées pour l'analyse des données. Résultats: Pendant les 12 premiers mois du traitement, 70% des cas ont montré une amélioration avec une régression significative de leurs tumeurs. L'âge des patients, le stade de la tumeur, le nombre de lésions osseuses, les niveaux de phosphatase alcalines et acides sériques préopératoires étaient des facteurs prédictifs de survie indépendants et significatifs (p = 0.0015, 0.002, 0.001, 0.0002 et 0.028, respectivement), tandis que le taux sérique de PSA pré thérapeutique, le grade de la tumeur et le type de traitement hormonal utilisé (castration ou BAT) n'étaient pas significativement prédictifs de l'évolution des patients (p = 0.18, 0.82 et 0.47, respectivement). Essentiellement, le niveau de PSA et le nombre de lésions osseuses pendant les 12 premiers mois de suivi étaient des facteurs prédictifs significatifs du statut global de survie de la maladie (p=0.001 et 0.028, respectivement). La période moyenne de suivi des cas vivants était de 39.42 mois s'étendant de 6 - 171 mois. Parmi les 222 cas 110 cas (51.6%) ont eu une progression de la maladie pendant un intervalle de temps moyen de 59.4 mois, alors que la mortalité était de 118 cas (53.2%) pendant un intervalle moyen de temps de 59.9 mois. Conclusion: L'âge du patient, le stade de la tumeur, le taux sérique de phosphatase alcaline et acide, comme le taux de PSA pré thérapeutique et le nombre de lésions osseuses étaient des facteurs prédictifs indépendants et significatifs de l'évolution du cancer chez les patients présentant un cancer avancé de la prostate. Cependant, une analyse de survie par rapport au type de traitement n'a pas indiqué une différence statistiquement significative entre les résultats de la castration et le BAT. (Af J Urology: 2003 9(2):94-101